Citius Oncology, Inc. CTOR Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount?
- Citius Oncology, Inc. (CTOR) reported valuation allowance, deferred tax asset, increase (decrease), amount of $1.92M in Q3 2025.
- How has Citius Oncology, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?
- Citius Oncology, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount increased by 55.9% year-over-year, from $1.23M to $1.92M.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- Tracks the net change in the valuation allowance established against deferred tax assets, reflecting changes in the likelihood of realizing future tax benefits. An increase suggests reduced confidence in utilizing tax assets, often due to sustained losses.